FDA
-
-
-
-
-
-
-
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
-
-
-
-
-
-
-
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
-
-
-
-
-
-
-
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
-
-
-
-
-
-
-
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation
-
-
-
-
-
-
-
Entera Bio to present EB613 osteoporosis data at menopause conference
-
-
-
-
-
-
-
Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
-
-
-
-
-
-
-
OPKO Health (OPK) and Entera Bio (ENTX) Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation
-
324,763 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

